# Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

> **NCT06231680** · PHASE2 · UNKNOWN · sponsor: **Henan Cancer Hospital** · enrollment: 132 (estimated)

## Conditions studied

- Lung Cancer, Nonsmall Cell
- Esophageal Carcinoma

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Thalidomide 50mg
- **DRUG:** Thalidomide 100mg
- **DRUG:** Thalidomide 200mg
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT06231680
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01-19
- **Primary completion:** 2024-06-30
- **Final completion:** 2025-09-30
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2024-03-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06231680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06231680, "Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06231680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*